MAGE-E1 Inhibitors
MAGE-E1 is a protein that belongs to the extensive MAGE (Melanoma Antigen Gene) family, known for its expression mainly in various cancer cells and, in a typical physiological state, restricted to the testes. MAGE-E1, like other cancer-testis antigens, is implicated in the intricate processes of cell cycle regulation and immune recognition. The expression of MAGE-E1 in cancerous tissues, as opposed to healthy differentiated tissues, marks it as a focal point of interest in the study of cancer biology. Due to its restricted expression pattern, MAGE-E1 has garnered attention for its potential role as a biomarker for cancer diagnosis and as a target for cancer prognosis studies. The regulation of MAGE-E1 expression is complex, involving a myriad of cellular mechanisms including DNA methylation, histone modification, and the interplay of various transcription factors.
In the realm of molecular biology and biochemistry, several chemical compounds have been identified that can potentially inhibit the expression of genes like MAGE-E1. These inhibitors typically work by interfering with the epigenetic and transcriptional machinery of the cell. For instance, DNA methyltransferase inhibitors such as 5-Azacytidine and Decitabine can lead to the reduction of MAGE-E1 expression by inducing the demethylation of its gene promoter. This demethylation can reactivate genes that are otherwise silenced in cancer cells. Similarly, histone deacetylase (HDAC) inhibitors, including Vorinostat and Entinostat, might decrease MAGE-E1 expression through the alteration of chromatin structure, thereby impeding the transcriptional activity of genes associated with cancer progression. Other compounds such as JQ1, which targets bromodomain-containing proteins, could disrupt the reading of acetylation marks, thereby influencing the expression of genes like MAGE-E1. It's important to note that these compounds act upon general cellular pathways and their influence on MAGE-E1 specifically is a subject of ongoing research. Their utility lies within the realm of scientific inquiry, where understanding the modulation of gene expression can provide insights into the fundamental workings of cellular biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
This cytidine analog could hypothetically lead to the demethylation of the MAGE-E1 promoter region, resulting in decreased expression in cancer cells by reactivating silenced genes. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid may downregulate MAGE-E1 by increasing the acetylation of histones associated with the gene's promoter, thereby altering the accessibility of the transcriptional machinery. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $210.00 $242.00 $1434.00 | 2 | |
By inhibiting class I HDAC enzymes, mocetinostat could reduce the expression of MAGE-E1 through the hyperacetylation of histones, leading to a less permissive state for gene transcription. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
Disulfiram may reduce MAGE-E1 expression by disrupting the degradation pathway of transcription factors that are critical for MAGE-E1 expression, leading to their accumulation and feedback inhibition. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine could inhibit the DNA methylation of the MAGE-E1 gene promoter, potentially leading to the reactivation of tumor suppressor genes that downregulate MAGE-E1 expression. | ||||||
Histone Lysine Methyltransferase Inhibitor Inhibitor | 935693-62-2 (free base) | sc-202651 | 5 mg | $148.00 | 4 | |
This compound might decrease MAGE-E1 expression by inhibiting G9a histone methyltransferase, leading to reduced methylation of histone H3K9 near the MAGE-E1 gene and altering gene expression. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $128.00 $505.00 | 2 | |
RG 108 has the potential to decrease MAGE-E1 expression by blocking DNA methyltransferases, which may result in hypomethylation of the gene's promoter and reduced transcription. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $226.00 $846.00 | 1 | |
JQ1 may inhibit the expression of MAGE-E1 by binding to bromodomains of BET proteins, thereby displacing them from chromatin and interfering with the transcription of cancer-related genes. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $88.00 $208.00 | 24 | |
MS-275 could lead to a decrease in MAGE-E1 expression by selectively altering the acetylation level of histones bound to the MAGE-E1 gene, changing the chromatin structure to a closed conformation. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $214.00 $622.00 | 1 | |
By inhibiting HDAC, romidepsin may specifically promote the acetylation of histone proteins associated with the MAGE-E1 gene, thereby reducing the transcriptional activity of the gene. | ||||||